Research programme: monoclonal antibodies mimicking T cell receptors- Agenus

Drug Profile

Research programme: monoclonal antibodies mimicking T cell receptors- Agenus

Latest Information Update: 13 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PhosImmune; Pure MHC
  • Developer Agenus; Pure MHC
  • Class Cancer vaccines; Heat shock proteins; Monoclonal antibodies; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Dec 2016 Agenus Inc. plans a phase I trial for Cancer in USA (NCT02992977)
  • 27 Jan 2016 Preclinical trials in Cancer in USA (Parenteral)
  • 23 Dec 2015 PhosImmune was acquired by Agenus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top